Efficacy and survival analysis of TACE combined with radiofrequency ablation in the treatment of liver metastasis from colorectal cancer

X. Yi, T. Yan, Ding Bo, Liu Yuanzhi, L. Dongyang, Zhang Yan
{"title":"Efficacy and survival analysis of TACE combined with radiofrequency ablation in the treatment of liver metastasis from colorectal cancer","authors":"X. Yi, T. Yan, Ding Bo, Liu Yuanzhi, L. Dongyang, Zhang Yan","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.006","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the clinical efficacy and safety of transhepatic arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of colorectal cancer with liver metastasis. \n \n \nMethods \nThe data of 92 patients with colorectal cancer with liver metastasis admitted to Nanyang First People′s Hospital of Henan Province from January 2014 to January 2016 were retrospectively analyzed. A total of 46 patients treated with TACE were selected as the TACE group, and another 46 patients treated with TACE and RFA were selected as the combined group. The clinical efficacies of the two groups were compared, and the changes of Karnofsky functional status (KPS) scores before and after treatment in the two groups were analyzed. The incidences of complications in the two groups were calculated. Patients in the two groups were followed up, and the progress-free survival (PFS) and overall survival (OS) were calculated. \n \n \nResults \nThe disease control rate of the combined group was 82.61% (38/46), and that of the TACE group was 63.04% (29/46). The disease control rate of the combined group was higher than that of the TACE group (χ2=4.449, P=0.035). Before treatment, the KPS scores of the combined group and the TACE group were 71.84±4.37, 72.22±4.26, with no statistically significant difference (t=0.423, P=0.673). After treatment, the KPS scores of the two groups were higher than those before treatment, and the KPS score of the combined group was higher than that of the TACE group (79.81±6.15 vs. 75.86±6.02; t=3.108, P=0.003). The incidence of complications was 54.35% (25/46) in the combined group and 41.30% (19/46) in the TACE group. The difference between the two groups was not statistically significant (χ2=1.568, P=0.210). The median PFS and OS in the TACE group were 12.6 and 20.7 months, and those in the combined group were 18.9 and 28.2 months. The PFS and OS of the combined group were longer than those of the TACE group (χ2=72.025, P<0.001; χ2=26.580, P<0.001). \n \n \nConclusion \nTACE combined with RFA is effective in the treatment of liver metastasis of colorectal cancer, which can effectively improve the KPS score of patients, prolong the PFS and OS, and do not increase the risk of complications. \n \n \nKey words: \nColorectal neoplasms; Neoplasm metastasis; Hepatic arterial chemoembolization; Radiofrequency ablation; Survival analysis","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"90 1","pages":"673-677"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To observe the clinical efficacy and safety of transhepatic arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of colorectal cancer with liver metastasis. Methods The data of 92 patients with colorectal cancer with liver metastasis admitted to Nanyang First People′s Hospital of Henan Province from January 2014 to January 2016 were retrospectively analyzed. A total of 46 patients treated with TACE were selected as the TACE group, and another 46 patients treated with TACE and RFA were selected as the combined group. The clinical efficacies of the two groups were compared, and the changes of Karnofsky functional status (KPS) scores before and after treatment in the two groups were analyzed. The incidences of complications in the two groups were calculated. Patients in the two groups were followed up, and the progress-free survival (PFS) and overall survival (OS) were calculated. Results The disease control rate of the combined group was 82.61% (38/46), and that of the TACE group was 63.04% (29/46). The disease control rate of the combined group was higher than that of the TACE group (χ2=4.449, P=0.035). Before treatment, the KPS scores of the combined group and the TACE group were 71.84±4.37, 72.22±4.26, with no statistically significant difference (t=0.423, P=0.673). After treatment, the KPS scores of the two groups were higher than those before treatment, and the KPS score of the combined group was higher than that of the TACE group (79.81±6.15 vs. 75.86±6.02; t=3.108, P=0.003). The incidence of complications was 54.35% (25/46) in the combined group and 41.30% (19/46) in the TACE group. The difference between the two groups was not statistically significant (χ2=1.568, P=0.210). The median PFS and OS in the TACE group were 12.6 and 20.7 months, and those in the combined group were 18.9 and 28.2 months. The PFS and OS of the combined group were longer than those of the TACE group (χ2=72.025, P<0.001; χ2=26.580, P<0.001). Conclusion TACE combined with RFA is effective in the treatment of liver metastasis of colorectal cancer, which can effectively improve the KPS score of patients, prolong the PFS and OS, and do not increase the risk of complications. Key words: Colorectal neoplasms; Neoplasm metastasis; Hepatic arterial chemoembolization; Radiofrequency ablation; Survival analysis
TACE联合射频消融治疗结直肠癌肝转移的疗效及生存期分析
目的观察经肝动脉化疗栓塞(TACE)联合射频消融(RFA)治疗结直肠癌伴肝转移的临床疗效和安全性。方法回顾性分析2014年1月至2016年1月河南省南阳市第一人民医院收治的92例结直肠癌合并肝转移患者的资料。共选择46例接受TACE治疗的患者作为TACE组,另选择46例接受TACE和RFA治疗的患者作为联合组。比较两组临床疗效,分析两组治疗前后Karnofsky功能状态(KPS)评分的变化。计算两组患者的并发症发生率。对两组患者进行随访,计算无进展生存期(PFS)和总生存期(OS)。结果联合组疾病控制率为82.61% (38/46),TACE组疾病控制率为63.04%(29/46)。联合治疗组疾病控制率高于TACE治疗组(χ2=4.449, P=0.035)。治疗前,联合组与TACE组KPS评分分别为71.84±4.37、72.22±4.26,差异无统计学意义(t=0.423, P=0.673)。治疗后,两组患者KPS评分均高于治疗前,且联合组KPS评分高于TACE组(79.81±6.15∶75.86±6.02;t = 3.108, P = 0.003)。联合组并发症发生率为54.35% (25/46),TACE组为41.30%(19/46)。两组间差异无统计学意义(χ2=1.568, P=0.210)。TACE组的中位PFS和OS分别为12.6和20.7个月,联合组的中位PFS和OS分别为18.9和28.2个月。联合治疗组PFS、OS均长于TACE治疗组(χ2=72.025, P<0.001;χ2 = 26.580,P < 0.001)。结论TACE联合RFA治疗结直肠癌肝转移有效,可有效提高患者KPS评分,延长PFS和OS,且不增加并发症发生风险。关键词:结直肠肿瘤;肿瘤转移;肝动脉化疗栓塞;射频消融术;生存分析
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
12123
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信